Suggested remit: To appraise the clinical and cost effectiveness of nivolumab within its marketing authorisation for maintenance treatment of extensive-stage small-cell lung cancer after chemotherapy.
Referred 22/07/2016
 
Status Suspended
Process STA 2018
ID number 1264

Project Team

Project lead Emily Richards

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
16 September 2019 Suspended, Referred 22/07/2016
16 September 2019 The Department for Health and Social Care has asked NICE to carry out an appraisal of nivolumab for maintenance treatment of extensive stage small-cell lung cancer after chemotherapy. For information, the company have advised that they are no longer pursuing a Marketing Authorisation Application from the European Medicines Agency for this indication at this time. Therefore, NICE has decided to suspend this appraisal from its current work programme. As this appraisal has been referred NICE will continue to monitor any development and will update interested parties if the situation changes.
17 October 2018 - 14 November 2018 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators
22 July 2016 Referral
22 July 2016 In progress, Topic referred

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance